Mural Oncology shareholders to receive fixed $2.035 per share as XOMA Royalty deal nears closing

Mural Oncology plc has confirmed that shareholders will receive a fixed cash consideration of $2.035 per ordinary share at the closing of its acquisition by XOMA Royalty Corporation, bringing final clarity to a transaction that has been closely followed across the small-cap biotechnology and royalty investment ecosystem. The final determination removed the variable additional payment component that had been embedded in the original transaction framework, locking in a definitive cash exit for investors ahead of the expected early December 2025 closing.

The confirmation eliminates lingering uncertainty around whether excess net cash at closing could have triggered an incremental payout of up to $0.205 per share. With the additional price now formally set at zero, shareholders will receive only the base consideration, translating into a clean, all-cash transaction with no post-closing performance or balance-sheet contingencies. Market reaction across Mural Oncology’s Nasdaq-listed shares has reflected acceptance of the finalized economics, with recent trading clustering tightly around the announced cash price as arbitrage spreads compress.

XOMA Royalty Corporation is executing the transaction through its wholly owned acquisition vehicle, XRA 5 Corp., under an Irish High Court–sanctioned scheme of arrangement. The structure is standard for U.K.- and Ireland-domiciled life sciences deals and enables the compulsory acquisition of 100% of Mural Oncology’s issued and outstanding share capital following shareholder and court approval. With shareholder votes already secured at overwhelming levels in October, only final court sanction and customary procedural formalities remain before funds are distributed.

How the final $2.035 per share payout reshapes return expectations for Mural Oncology investors

When XOMA Royalty Corporation first announced the acquisition agreement in August 2025, the two-tier consideration structure introduced potential upside tied to Mural Oncology’s closing net cash position. The base cash portion of $2.035 per share was supplemented by a conditional additional price of up to $0.205 per share if cash on hand exceeded a defined threshold. That mechanism was designed to ensure that any surplus capital beyond transaction assumptions would be efficiently returned to shareholders rather than retained by the acquirer.

The final determination that the additional payout is zero effectively signals that Mural Oncology’s net cash position at closing fell within the modeled range anticipated at signing. For long-term shareholders, the outcome crystallizes a firm but capped return and brings closure to a speculative period where expectations for incremental upside had remained open. From a valuation perspective, the confirmed price implies a modest premium relative to Mural Oncology’s pre-deal trading levels earlier in the year, though substantially below the historical peaks seen during earlier clinical development cycles.

For arbitrage-oriented investors, the definitive pricing compresses risk but also limits reward. With the stock trading narrowly below the $2.035 consideration, the remaining spread largely reflects time value and minimal execution risk tied to legal finalization. The absence of upside optionality may dampen short-term speculative trading but enhances certainty for institutional holders focused on capital preservation rather than asymmetric payoff.

Why XOMA Royalty opted for a fixed cash structure in a volatile clinical-stage biotech market

XOMA Royalty Corporation has steadily repositioned itself over the past several years as a diversified intellectual-property and royalty investment platform rather than a traditional drug developer. Its acquisition strategy has increasingly emphasized assets that offer defined cash flows or monetizable intellectual property rather than exposure to binary clinical trial outcomes. The Mural Oncology transaction aligns neatly with that risk-adjusted capital deployment model.

By locking the deal structure into a fixed cash consideration with no post-closing earn-outs or milestone-linked payments, XOMA Royalty eliminates integration volatility and neutralizes exposure to late-stage clinical failure risk. Mural Oncology’s pipeline, while scientifically compelling within immuno-oncology, remains in the high-uncertainty segment of drug development where valuation can swing sharply on interim data. The fixed-price approach transfers that residual scientific risk away from XOMA Royalty’s balance sheet in exchange for immediate ownership of any residual IP value, while allowing Mural shareholders to exit without further dilution risk.

The structure also reflects the broader funding environment for small and mid-cap biopharmaceutical companies. Capital markets for early-stage oncology developers remain selective in late 2025, with financing costs elevated and investor appetite tilted toward assets with nearer-term revenue visibility. Royalty-focused aggregators like XOMA are increasingly filling the liquidity gap by offering exit paths that emphasize certainty over speculative upside.

What shareholder approvals and Irish High Court sanction mean for the final closing mechanics

Mural Oncology shareholders overwhelmingly approved the scheme of arrangement at court-convened meetings held in October 2025, satisfying the statutory requirements under Irish corporate law for the transaction to proceed. The approval thresholds, which require both a majority in number of shareholders voting and at least 75% in value of the shares represented, were met comfortably, signaling broad investor support for the acquisition terms.

The remaining procedural step is formal sanction by the Irish High Court, which reviews the fairness, transparency, and legal compliance of the scheme. This process is typically administrative for transactions that have already secured overwhelming shareholder backing and where no formal objections have been lodged. Upon receipt of court approval and completion of required filings, the scheme will become effective, triggering the transfer of Mural Oncology’s shares to XRA 5 Corp. and the distribution of cash consideration to eligible shareholders.

Settlement is expected shortly thereafter, with funds remitted through standard custodial and clearing channels. Following completion, Mural Oncology’s Nasdaq listing is expected to be cancelled, formally ending its status as a publicly traded biotechnology issuer.

How the transaction influences XOMA Royalty’s balance-sheet strategy and asset portfolio weighting

For XOMA Royalty Corporation, the acquisition of Mural Oncology represents a modest but strategically consistent deployment of capital within its expanding portfolio of life-sciences assets. XOMA has spent 2024 and 2025 reshaping its balance sheet toward a blend of royalty streams, royalty-backed debt instruments, and selectively acquired IP-rich operating companies. The addition of Mural Oncology strengthens that IP-centric approach without materially increasing clinical development exposure.

From an accounting standpoint, the transaction is expected to be treated as an asset acquisition rather than a platform-scale operating merger. That distinction limits integration costs and preserves XOMA Royalty’s lean operating structure. It also allows the company to maintain its investor narrative as a non-operating royalty aggregator rather than shifting into a hybrid drug-development model.

Strategically, the deal continues a pattern of opportunistic acquisitions targeting companies whose capital structures, cash burn profiles, or market valuations have become misaligned with long-term development timelines. For XOMA, such deals provide optionality on future IP monetization while maintaining strict financial discipline.

What the Mural Oncology acquisition says about consolidation pressures across the small-cap oncology sector

The takeover of Mural Oncology by XOMA Royalty reflects broader consolidation currents reshaping the clinical-stage oncology landscape. Many early- and mid-stage oncology developers that raised capital at peak valuations during the biotechnology funding boom of 2020 to 2022 now face compressed share prices, extended development timelines, and constrained access to fresh equity capital. In that environment, fixed-price acquisitions by financially disciplined buyers offer one of the few viable liquidity paths for long-term shareholders.

The absence of an additional cash payout in this transaction also underscores how balance-sheet durability has become a decisive factor in exit pricing. Companies that preserve surplus net cash approaching closing can sometimes unlock incremental value through net-cash adjustments. Those operating closer to modeled burn-rate assumptions, as Mural Oncology appears to have done, typically see only base consideration delivered.

For the broader sector, the deal reinforces the bifurcation between programs that attract large pharmaceutical buyers seeking late-stage assets and those that appeal primarily to financial acquirers focused on IP optionality and capital efficiency. XOMA Royalty clearly falls into the latter category, and its continued acquisition activity signals that this financial buyer segment remains active even amid cautious biotech sentiment.

How Nasdaq investors are interpreting MURA and XOMA share-price behavior around the transaction

Mural Oncology shares have gravitated toward the $2.035 consideration level in recent sessions, reflecting a tightening arbitrage spread as closing approaches. Volatility has declined substantially since shareholder approval was announced, suggesting that market participants now view execution risk as low. Daily volume has remained elevated relative to pre-deal averages, consistent with position rotation among arbitrage funds and final rebalancing by retail holders.

XOMA Royalty Corporation’s stock, meanwhile, has exhibited relatively muted reaction to the final cash determination. That stability reflects the modest scale of the transaction relative to XOMA’s overall asset base and balance-sheet capacity. Investors in XOMA continue to focus more heavily on the company’s broader royalty portfolio performance, capital deployment pipeline, and macro conditions for life-sciences IP monetization.

From a sentiment perspective, institutional positioning suggests neutral-to-constructive expectations for both names into year-end. Mural Oncology is largely viewed as a completed trade, while XOMA Royalty retains optionality tied to future acquisition announcements and portfolio monetization events.

What investors should monitor as the acquisition enters its final legal phase

With the economic terms now locked, attention shifts to procedural completion rather than valuation. Investors should monitor the timing of the Irish High Court sanction hearing, the publication of the effective date of the scheme, and settlement mechanics communicated through brokers and custodians. Any deviations from the anticipated early December 2025 timetable would likely be administrative rather than structural, given the strength of prior shareholder approvals.

Market participants will also watch whether XOMA Royalty provides additional disclosure on post-closing integration, IP strategy, or potential asset monetization tied to Mural Oncology’s programs. While such details are not required for closing, incremental guidance could shape sentiment around the longer-term strategic value of the acquisition within XOMA’s portfolio.

For Mural Oncology shareholders, the remaining weeks primarily involve execution patience rather than strategic decision-making. Once court sanction is secured and the scheme becomes effective, the investment thesis converts from a public equity position into a straightforward cash settlement, formally ending Mural Oncology’s journey as an independent public biotechnology company.